Welcome!

News Feed Item

Tetra Bio-Pharma Continues Forward into the Veterinary Ophthalmology Market by Entering into an Agreement with Drs. Cullen and Webb

OTTAWA, ONTARIO -- (Marketwired) -- 10/13/17 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the addition of two members to its clinical advisory board for the veterinary market - Dr. Cheryl Cullen, an American Board-certified Veterinary Ophthalmologist, and Dr. Webb, an American Board of Veterinary Ophthalmology (ABVO) Resident.

Drs. Cullen and Webb have extensive clinical experience as veterinary ophthalmologists treating a broad range of ocular disease in companion animals. Their expert guidance, practical experience and clinical access to patients will play a critical role in the ability and success of Tetra to develop and commercialize cannabinoid-based drugs for the treatment of ocular indications. These indications in domestic animals include inflammation and pain following ocular surgery and chronic ophthalmic disease. Under the agreement, Drs. Cullen and Webb's role will be to assist Tetra's R&D team in the design of veterinary clinical trials exploring the therapeutic use of cannabinoids in multiple ocular indications and to conduct these trials at their private clinic in New Brunswick, which are expected to begin in Q1 2018.

According to the American Pet Products Association, pet owners spent $15.75 billion dollars on veterinary care in 2016, with a nearly 4% growth per year attributed to new advances in health care and available services. Indeed, specialty pet care has exploded: in a 2013 online US poll, 47% of respondents said they've sought veterinary specialty care for their pet, and of those, 27% said they spent more than $2,500 on these services. The field of ophthalmology is rapidly advancing and patients are often referred to veterinary specialists in this area, granting the owner treatment options for pathologies that that did not previously exist. According to a review published in 2010 by the Comparative Ocular Pathology Laboratory of Wisconsin, 29% of eye diseases studied in a population of 15,000 dogs and 5,200 cats involved inflammation. With the help of Drs. Webb and Cullen, Tetra is looking to capitalize on these trends by further developing PPP003 as a novel treatment for veterinary inflammation and pain associated with ophthalmic pathologies.

"This recent addition of Drs. Cullen and Webb to our growing veterinary clinical advisory board stands to further diversify our panel of experts into the area of ophthalmology as we accelerate and expand our existing cannabinoid-based drug pipeline into the veterinary market. As well, Dr. Webb's formal training and experience in the area of veterinary neurology will be an asset to our veterinary program because of the potential effects of cannabinoids on the nervous system," states Dr. Guy Chamberland, Chief Scientific Officer of Tetra.

About Dr. Cheryl Cullen, DVM, MVetSc, DACVO and Dr. Aubrey Webb, DVM, PhD (neuroscience), ABVO Resident in Ophthalmology:

Dr. Cullen received a DVM from the Atlantic Veterinary College, completed both a small animal internship and a Masters of Veterinary Science and Veterinary Ophthalmology residence at the Western College of Veterinary Medicine. Dr. Cullen furthered her training through the renowned Lancaster Course in Ophthalmology at Massachusetts Eye and Ear Infirmary and the William Magrane Basic Science Course in Veterinary and Comparative Ophthalmology. Dr. Cullen is board-certified by the American College of Veterinary Ophthalmologists.

Dr. Webb received a DVM from the Western College of Veterinary Medicine and a PhD in the field of neuroscience from University of Saskatchewan. He also has formal training in several areas of neuroscience, including veterinary neurology, neurosurgery, neuropathology and clinical electrodiagnostics and was the recipient of a Canadian Institutes of Health Research post-doctoral fellowship in the area of spinal cord research. Presently, Dr. Webb is an American board of Veterinary Ophthalmology approved Resident.

Both Drs. Cullen and Webb are founding faculty members of the University of Calgary's faculty of Veterinary Medicine and they have several peer-review publications in the areas of comparative ophthalmology and clinical veterinary neurology. They run veterinary practice, CullenWebb Animal Eye Specialists, located in Riverview New Brunswick (http://www.cullenwebb.com/) specializing in treating ocular disease in pets.

About PPP003:

PPP003 is a cannabinoid-based eye drop currently being developed to treat ocular pain and inflammatory disease in humans and animals.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE: TBP)(OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Contacts:
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
[email protected]

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
The challenges of aggregating data from consumer-oriented devices, such as wearable technologies and smart thermostats, are fairly well-understood. However, there are a new set of challenges for IoT devices that generate megabytes or gigabytes of data per second. Certainly, the infrastructure will have to change, as those volumes of data will likely overwhelm the available bandwidth for aggregating the data into a central repository. Ochandarena discusses a whole new way to think about your next...
So the dumpster is on fire. Again. The site's down. Your boss's face is an ever-deepening purple. And you begin debating whether you should join the #incident channel or call an ambulance to deal with his impending stroke. Yes, we know this is a developer's fault. There's plenty of time for blame later. Postmortems have a macabre name because they were once intended to be Viking-like funerals for someone's job. But we're civilized now. Sort of. So we call them post-incident reviews. Fires are ne...
Whenever a new technology hits the high points of hype, everyone starts talking about it like it will solve all their business problems. Blockchain is one of those technologies. According to Gartner's latest report on the hype cycle of emerging technologies, blockchain has just passed the peak of their hype cycle curve. If you read the news articles about it, one would think it has taken over the technology world. No disruptive technology is without its challenges and potential impediments t...
Hackers took three days to identify and exploit a known vulnerability in Equifax’s web applications. I will share new data that reveals why three days (at most) is the new normal for DevSecOps teams to move new business /security requirements from design into production. This session aims to enlighten DevOps teams, security and development professionals by sharing results from the 4th annual State of the Software Supply Chain Report -- a blend of public and proprietary data with expert researc...
CloudEXPO New York 2018, colocated with DevOpsSUMMIT and DXWorldEXPO New York 2018 will be held November 12-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI and Machine Learning to one location.
DXWorldEXPO LLC announced today that Nutanix has been named "Platinum Sponsor" of CloudEXPO | DevOpsSUMMIT | DXWorldEXPO New York, which will take place November 12-13, 2018 in New York City. Nutanix makes infrastructure invisible, elevating IT to focus on the applications and services that power their business. The Nutanix Enterprise Cloud Platform blends web-scale engineering and consumer-grade design to natively converge server, storage, virtualization and networking into a resilient, softwar...
CloudEXPO | DevOpsSUMMIT | DXWorldEXPO are the world's most influential, independent events where Cloud Computing was coined and where technology buyers and vendors meet to experience and discuss the big picture of Digital Transformation and all of the strategies, tactics, and tools they need to realize their goals. Sponsors of DXWorldEXPO | CloudEXPO benefit from unmatched branding, profile building and lead generation opportunities.
The digital transformation is real! To adapt, IT professionals need to transform their own skillset to become more multi-dimensional by gaining both depth and breadth of a wide variety of knowledge and competencies. Historically, while IT has been built on a foundation of specialty (or "I" shaped) silos, the DevOps principle of "shifting left" is opening up opportunities for developers, operational staff, security and others to grow their skills portfolio, advance their careers and become "T"-sh...
Lori MacVittie is a subject matter expert on emerging technology responsible for outbound evangelism across F5's entire product suite. MacVittie has extensive development and technical architecture experience in both high-tech and enterprise organizations, in addition to network and systems administration expertise. Prior to joining F5, MacVittie was an award-winning technology editor at Network Computing Magazine where she evaluated and tested application-focused technologies including app secu...
DXWorldEXPO LLC announced today that Big Data Federation to Exhibit at the 22nd International CloudEXPO, colocated with DevOpsSUMMIT and DXWorldEXPO, November 12-13, 2018 in New York City. Big Data Federation, Inc. develops and applies artificial intelligence to predict financial and economic events that matter. The company uncovers patterns and precise drivers of performance and outcomes with the aid of machine-learning algorithms, big data, and fundamental analysis. Their products are deployed...
ICC is a computer systems integrator and server manufacturing company focused on developing products and product appliances to meet a wide range of computational needs for many industries. Their solutions provide benefits across many environments, such as datacenter deployment, HPC, workstations, storage networks and standalone server installations. ICC has been in business for over 23 years and their phenomenal range of clients include multinational corporations, universities, and small busines...
This sixteen (16) hour course provides an introduction to DevOps, the cultural and professional movement that stresses communication, collaboration, integration and automation in order to improve the flow of work between software developers and IT operations professionals. Improved workflows will result in an improved ability to design, develop, deploy and operate software and services faster.
Headquartered in Plainsboro, NJ, Synametrics Technologies has provided IT professionals and computer systems developers since 1997. Based on the success of their initial product offerings (WinSQL and DeltaCopy), the company continues to create and hone innovative products that help its customers get more from their computer applications, databases and infrastructure. To date, over one million users around the world have chosen Synametrics solutions to help power their accelerated business or per...
All in Mobile is a place where we continually maximize their impact by fostering understanding, empathy, insights, creativity and joy. They believe that a truly useful and desirable mobile app doesn't need the brightest idea or the most advanced technology. A great product begins with understanding people. It's easy to think that customers will love your app, but can you justify it? They make sure your final app is something that users truly want and need. The only way to do this is by ...
Authorization of web applications developed in the cloud is a fundamental problem for security, yet companies often build solutions from scratch, which is error prone and impedes time to market. This talk shows developers how they can (instead) build on-top of community-owned projects and frameworks for better security.Whether you build software for enterprises, mobile, or internal microservices, security is important. Standards like SAML, OIDC, and SPIFFE help you solve identity and authenticat...